undamentalytics Newsletter
Sign in

CME Group income statement

In fiscal 2025, CME Group reported revenue of $6.52bn, up 6.4% on the year before, operating income of $4.23bn (a 64.9% margin) and net income of $4.07bn, or $11.16 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue2,6133,0043,2812,9152,9363,1133,3273,5953,6454,3094,8684,8844,6905,0195,5796,1306,5216,972
Operating income1,5891,8312,0211,6921,6371,7681,9892,2012,3112,6082,5882,6372,6453,0163,4363,9324,2304,578
Income before tax1,4381,7221,9371,6931,6011,7711,9572,2882,5262,7782,6902,7223,3743,4904,1544,5415,3315,772
Income tax612770122787623645710754−1,5378145746167377999271,0161,2581,356
Net income8269511,8128969771,1271,2471,5344,0631,9622,1172,1062,6372,6913,2263,5264,0724,430
Diluted EPS$2.48$2.86$5.43$2.70$2.92$3.35$3.69$4.53$11.94$5.71$5.91$5.87$7.29$7.40$8.86$9.67$11.16$12.28
Diluted shares (average)333m332m334m332m334m336m338m339m340m344m358m359m359m359m360m360m360m361m
EBITDA1,7151,9612,1501,8291,7721,9012,1182,3302,4242,7262,7462,7912,7933,1513,5624,0474,3374,687

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CME vs MCOCME vs COINCME vs NDAQCBOE vs CME

More: Financial Exchanges & Data stocks compared, Financials sector, rankings of US companies

Figures from CME Group's SEC filings (10-K and 10-Q), retrieved October 24, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to CME Group.